Multiple Myeloma · Active Clinical Trials
As of 2026-10-21, the full China registry snapshot contains 64 active multiple myeloma interventional trials across 31 provincial-level regions and 316 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
A Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 222 家
Target / Modality
Trispecific antibody targeting BCMA, GPRC5D, and CD3
ELRANATAMAB Post-Trial Access: An Open-Label, Single-Arm Study for Multiple Myeloma Study Participants Continuing in Pfizer-Sponsored ELRANATAMAB Clinical Studies
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Peking University Third Hospital、Shandong Provincial Hospital 等 7 家
Target / Modality
bispecific antibody
A Phase I/II Clinical Study of GC012F Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) 等 10 家
Target / Modality
CAR-T targeting both BCMA and CD19
A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 78 家
Target / Modality
Novel monoclonal antibody targeting CD38
A Multicenter, Non-Randomized, Open-Label Phase I/IIa Clinical Study Evaluating the Safety, Tolerability, and Efficacy of ICP-490 Monotherapy and in Combination with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Locations & Centers
Peking University People's Hospital、Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine、Shengjing Hospital of China Medical University 等 6 家
Target / Modality
Oral small-molecule "molecular glue" degrader
An Open-Label, Two-Arm, Multicenter, Randomized, Phase III Study Evaluating the Efficacy and Safety of ELRANATAMAB (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Study Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible or Deferred Transplant
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital, Zhejiang University School of Medicine 等 17 家
Target / Modality
BCMA × CD3 bispecific antibody
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Nanchang University、Peking University First Hospital 等 10 家
Target / Modality
Autologous BCMA/CD19 dual-targeting CAR-T
A Phase II, Open-label, Single-arm, Multicenter Clinical Study Evaluating the Efficacy and Safety of BCMA-targeted Chimeric Antigen Receptor T-cell Injection (CART-BCMA) in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital 等 25 家
Target / Modality
BCMA-targeted CAR-T cell therapy
A Phase 3, 2-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Locations & Centers
Beijing Chao-Yang Hospital, Capital Medical University (East Campus)、Xi'an International Medical Center Co., Ltd.、Peking University First Hospital 等 32 家
Target / Modality
Next-generation "molecular glue" degrader (CELMoD)
A Multicenter, Open-Label Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HMPL-506 in Hematologic Malignancies
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Nanfang Hospital of Southern Medical University、Qilu Hospital of Shandong University 等 13 家
Target / Modality
Small molecule targeted drug
An Open-Label, Single-Arm, Multicenter Clinical Trial Evaluating the Efficacy and Safety of Pomalidomide Capsules Combined with Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
Beijing Chaoyang Hospital, Capital Medical University、Puyang Oilfield General Hospital、Shangqiu First People's Hospital 等 28 家
Target / Modality
Pomalidomide
A Phase III, Randomized Study Comparing Teclistamab in Combination With Subcutaneous (SC) Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With SC Daratumumab and Lenalidomide (Tal-DR) Versus SC Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Not Eligible or Not Planned for Autologous Stem Cell Transplantation as Initial Therapy
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital 等 32 家
Target / Modality
BCMA × CD3 bispecific antibody (MajestTEC-7 study)
A Phase I Clinical Trial of HRS-3738 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital 等 37 家
Target / Modality
Small molecule oral targeted drug / Next-generation EED (embryonic ectoderm development protein) inhibitor
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KYS202002A Monoclonal Antibody Injection in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Beijing Chaoyang Hospital, Capital Medical University、Shengjing Hospital of China Medical University、Zhongshan Hospital, Fudan University 等 7 家
Target / Modality
Recombinant humanized anti-CD38 monoclonal antibody
A Randomized, Controlled, Multicenter, Open-Label Phase III Study Evaluating the Efficacy and Safety of QLS32015 for Injection Monotherapy Versus Investigator's Choice of Regimen in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、First Affiliated Hospital of Kunming Medical University 等 82 家
Target / Modality
GPRC5D/CD3 bispecific antibody
A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of 6MW5311 in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and Multiple Myeloma
Locations & Centers
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine 等 8 家
Target / Modality
LILRB4 and CD3 bispecific antibody
A Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Locations & Centers
Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University 等 37 家
Target / Modality
Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GLB-002 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Locations & Centers
Peking University Cancer Hospital、Henan Cancer Hospital、Jiangxi Cancer Hospital 等 13 家
Target / Modality
Molecular glue degrader
An Open-Label, Multicenter Phase I Clinical Study of SHR-9539 Injection Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Multiple Myeloma
Locations & Centers
West China Hospital of Sichuan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 28 家
Target / Modality
BCMA × CD3-targeting bispecific antibody
A Phase I/II, Open-Label, Multicenter, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 Monotherapy or in Combination with Anticancer Agents in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Peking University People's Hospital、Shengjing Hospital of China Medical University (The Second Affiliated Hospital of China Medical University)、Sun Yat-sen University Cancer Center 等 4 家
Target / Modality
Antibody-drug conjugate (ADC)
An Open-Label, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of F182112 in Combination with Different Dosing Regimens for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Bengbu Medical University、The First Affiliated Hospital of Chongqing Medical University 等 44 家
Target / Modality
Recombinant Humanized Anti-BCMA/CD3 Bispecific Antibody for Injection
An International, Multicenter, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Continue to Benefit From an Isatuximab-Based Treatment Following Completion of a Phase I, II, or III Parent Study
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Royal North Shore Hospital、Instituto COI de Educacao e Pesquisa 等 21 家
Target / Modality
Anti-CD38 monoclonal antibody
A Multicenter, Open-label Phase II Study Evaluating QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、Nanyang Central Hospital 等 50 家
Target / Modality
T-cell redirecting bispecific antibody
A Multicenter, Open-label, Randomized Phase III Clinical Trial Comparing the Efficacy and Safety of GR1803 Injection Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received 1-3 Prior Lines of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、Henan Cancer Hospital 等 67 家
Target / Modality
BCMA-targeting bispecific antibody
A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetic Profile, Safety, Tolerability, and Immunogenicity of HLX15-SC Versus DARZALEX FASPRO; Combined with Lenalidomide-Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation
Locations & Centers
Zhongshan Hospital, Fudan University、Peking University Third Hospital、Guangzhou First People's Hospital 等 66 家
Target / Modality
Recombinant fully human anti-CD38 monoclonal antibody
A Phase 3, Multicenter, Randomized, Open-Label Study Comparing Venetoclax Plus Dexamethasone Versus Pomalidomide Plus Dexamethasone in Participants with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Guangdong Provincial People's Hospital、The First Affiliated Hospital of Soochow University 等 19 家
Target / Modality
Oral small molecule targeted drug (BCL-2 inhibitor)
A Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
Peking University People's Hospital、The First Affiliated Hospital of Henan University of Science and Technology、Qingdao Municipal Hospital 等 21 家
Target / Modality
GPRC5D × CD3 bispecific antibody
A Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Locations & Centers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital 等 39 家
Target / Modality
Trispecific antibody targeting BCMA, CD3, and GPRC5D
A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 45 家
Target / Modality
GPRC5D/BCMA/CD3 trispecific antibody
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
Locations & Centers
West China Hospital, Sichuan University、Henan Cancer Hospital、The First Affiliated Hospital of Nanchang University 等 26 家
Target / Modality
Small-molecule chemical drug
A Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CM313(SC) Injection as Monotherapy and in Combination with Other Antineoplastic Therapies in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 16 家
Target / Modality
Recombinant humanized anti-CD38 monoclonal antibody
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Locations & Centers
The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center 等 19 家
Target / Modality
BCMA × CD3 bispecific T-cell engager (BiTE)
A Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University 等 11 家
Target / Modality
GPRC5D × CD3-targeting bispecific antibody
A Phase III, Multicenter, Open-label, Randomized Study Evaluating the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 8)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sun Yat-sen University Cancer Center、Shengjing Hospital of China Medical University 等 11 家
Target / Modality
Antibody-drug conjugate (ADC) targeting BCMA